PIK3CA gene testing for breast cancer
Part of Cancer clinical trials.
This trial tests for a specific gene change (PIK3CA mutation) in your breast cancer cells. The results will help doctors decide if a targeted treatment is right for you. It's for people with hormone-receptor-positive, HER2-negative breast cancer that has spread and not yet been treated in that setting.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your breast cancer must be estrogen-receptor (ER) positive and/or progesterone-receptor (PgR) positive.
- Your breast cancer must be HER2-negative (test result 0, 1+, or 2+ with a negative FISH/CISH/SISH test).
- Your breast cancer must have spread to other parts of the body (advanced or metastatic), and you cannot have received any treatment for this stage yet.
- You must be willing to sign a consent form to take part in the study.
- You must be able to come for follow-up visits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a simple blood test to look for two specific gene changes (ESR-1 and gBRCA) in people with hormone receptor-positive, HER2-negative breast cancer that has spread. It aims to detect these mutations earlier and help guide future treatment decisions.
This trial tests an experimental drug called GenSci145, which may target cancers with a specific gene change called PIK3CA. The drug is given alone or with other treatments. The goal is to see if it can shrink tumors or slow cancer growth.
This trial tests a new pill (CGT6297) that targets cancer cells with a specific PIK3CA gene change. It may be an option for people with certain advanced solid tumors, including endometrial or breast cancer, after standard treatments have stopped working.
This study tests a new drug called inavolisib for people with early-stage breast cancer that has a specific genetic change (PIK3CA mutation). The goal is to see if adding this drug to standard hormone therapy is safe and effective before surgery.
This trial tests an experimental drug called K-1728 in people with advanced solid tumors that have a specific genetic change called PIK3CA. The goal is to see if the drug can shrink tumors or slow their growth.
This trial tests a new imaging agent (68Ga-pAKTi) that may help doctors see breast cancer cells with a PET/CT scan. It is for people with a specific genetic change in their tumor, and who have not yet had surgery to remove the cancer.
Hear when a new Breast Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.